Status:
COMPLETED
Sleep State in Lung Cancer: A Retrospective Analysis
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Lung Adenocarcinoma
Sleep Disorders, Circadian Rhythm
Eligibility:
All Genders
20-70 years
Brief Summary
Lung cancer remains the leading cause of cancer-related mortality globally, with tumor progression closely linked to the immune microenvironment. Sleep disorders (e.g., insomnia, obstructive sleep apn...
Detailed Description
Lung cancer is the second most common cancer and the leading cause of cancer-related death in the world, and its treatment and prognosis improvement are still major clinical challenges. In recent year...
Eligibility Criteria
Inclusion
- NSCLC or SCLC was diagnosed.
- Patients have received immunotherapy (e.g., PD-1/PD-L1 inhibitors) or standard treatment (chemotherapy/radiotherapy).
- Sleep disorder diagnoses and immune-related biomarkers fully recorded in medical records.
Exclusion
- The patient had a history of other malignant tumors.
- Key clinical data lacking.
- The presence of a serious psychiatric or neurologic condition.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06953492
Start Date
January 1 2018
End Date
January 1 2025
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhong Shan hospital
Shanghai, China